Author:
Martinovich Kelly M.,Shaw Nicole C.,Kicic Anthony,Schultz André,Fletcher Sue,Wilton Steve D.,Stick Stephen M.
Publisher
Springer Science and Business Media LLC
Reference98 articles.
1. Stein CA, Castanotto D (2017) FDA-approved oligonucleotide therapies in 2017. Mol Ther. 25(5): p. 1069–1075
2. FDA grants accelerated approval to first drug for Duchenne muscular dystrophy. U.S. Food and Drug Administration news release 19th September 2016; Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm521263.htm
3. FDA approves first drug for spinal muscular atrophy. U.S. Food and Drug Administration news release 23 December 2016; Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm534611.htm
4. Sterne-Weiler T, Sanford JR (2014) Exon identity crisis: disease-causing mutations that disrupt the splicing code. Genome Biol 15(1):201–201
5. Chan JH, Lim S, Wong WS (2006) Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 33(5–6):533–540
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献